Scientific Basis for a Newborn Screening for Cystinosis and Primary Hyperoxaluria

What this Trial Is About

Researchers are evaluating a genetic newborn screening program for two rare inherited diseases, cystinosis and primary hyperoxaluria (PH), in Germany. These diseases are not detected by routine newborn screening methods but have known common genetic mutations. The study aims to determine if including cystinosis and PH in the general newborn screening should be recommended by comparing early diagnosed infants to those diagnosed later by symptoms, assessing whether early diagnosis and treatment improve outcomes. The study tests newborns using the same dried blood spot card collected for routine newborn screening to detect specific common mutations in the genes associated with cystinosis and PH. If two mutations are found for cystinosis, parents are immediately informed and further diagnostics are arranged. For PH, if one mutation is detected, parents are asked to provide urine samples for additional testing. The study plans to screen 200,000 newborns by 2025, with possible program expansion based on results. Parents who consent allow molecular genetic testing and data sharing for follow-up. Confirmatory tests and clinical care referrals are organized for newborns with positive screening results. Researchers will track the number of newborns diagnosed with cystinosis and PH and those carrying heterozygous mutations. The study includes monitoring for up to 12 months and evaluates whether early detection leads to better health outcomes compared to traditional diagnosis methods.

Genetic Newborn Screening for Cystinosis and Primary Hyperoxaluria